cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Immunovant Inc
21 own
8 watching
Current Price
$28.67
$-0.07
(-0.24%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
2,746.78M
52-Week High
52-Week High
45.58000
52-Week Low
52-Week Low
15.39000
Average Volume
Average Volume
1.03M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization2,746.78M
icon52-Week High45.58000
icon52-Week Low15.39000
iconAverage Volume1.03M
iconDividend Yield--
iconP/E Ratio--
What does the Immunovant Inc do?
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Read More
How much money does Immunovant Inc make?
News & Events about Immunovant Inc.
Zolmax
10 months ago
Shares of Immunovant, Inc. (NASDAQ:IMVT Get Rating) have been assigned an average rating of Moderate Buy from the eleven brokerages that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and ten have given a buy rating to the ...
Zolmax
1 year ago
Immunovant, Inc. (NASDAQ:IMVT Get Rating) CEO Peter Salzmann sold 3,395 shares of the companys stock in a transaction on Tuesday, April 18th. The shares were sold at an average price of $15.27, for a total value of $51,841.65. Following the transaction, the chief executive officer now directly owns ...
Ticker Report
1 year ago
Immunovant, Inc. (NASDAQ:IMVT Get Rating) CFO Eva Renee Barnett sold 3,423 shares of the firms stock in a transaction on Tuesday, April 18th. The shares were sold at an average price of $15.27, for a total value of $52,269.21. Following the sale, the chief financial officer now ...
Zolmax
1 year ago
Immunovant, Inc. (NASDAQ:IMVT Get Rating) Research analysts at HC Wainwright lifted their FY2026 earnings per share estimates for Immunovant in a research note issued on Monday, March 20th. HC Wainwright analyst D. Tsao now anticipates that the company will post earnings per share of ($1.19) for the...
Benzinga
1 year ago
Latest Ratings for IMVT DateFirmActionFromTo Dec 2021Wells FargoInitiates Coverage OnEqual-Weight Nov 2021HC Wainwright & Co.MaintainsBuy Aug 2021BairdDowngradesOutperformNeutral View More Analyst Ratings for IMVT View the Latest Analyst Ratings read more...
Frequently Asked Questions
Frequently Asked Questions
What is Immunovant Inc share price today?
plus_minus_icon
Can Indians buy Immunovant Inc shares?
plus_minus_icon
How can I buy Immunovant Inc shares from India?
plus_minus_icon
Can Fractional shares of Immunovant Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Immunovant Inc stocks?
plus_minus_icon
What is today’s traded volume of Immunovant Inc?
plus_minus_icon
What is today’s market capitalisation of Immunovant Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Immunovant Inc?
plus_minus_icon
What percentage is Immunovant Inc down from its 52-Week High?
plus_minus_icon
What percentage is Immunovant Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$28.67
$-0.07
(-0.24%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00